Zoetis Inc dividend – Zoetis Increases Quarterly Dividend by 15% to $0.432/Share

🌥️Trending News

Zoetis Inc ($NYSE:ZTS)., a global animal health company, recently announced an increase in its quarterly dividend by 15% to $0.432 per share. This marks the sixth consecutive year that the company has increased its dividend, reflecting its financial strength and ongoing commitment to returning value to shareholders. Zoetis provides medicines and vaccines, diagnostics, biodevices and services to livestock, poultry, companion animals, and horse owners. It is the largest supplier of animal healthcare products in the world, based on revenue. The company’s products range from preventive medicines to treatments for both companion animals and farm animals.

The dividend increase is an indication of the company’s confidence in its future growth prospects and its ability to deliver long-term value to shareholders. It also demonstrates Zoetis’ commitment to providing strong and consistent returns to its shareholders. Overall, Zoetis has demonstrated a strong commitment to its shareholders by increasing its dividend and delivering consistent returns. The company’s financial position and outlook remain strong, and the dividend increase is a sign of its commitment to rewarding shareholders for their investments.

Dividends – Zoetis Inc dividend

ZOETIS INC has recently announced that it is increasing its quarterly dividend by 15% to $0.432/share. This marks the third consecutive year of increased dividends for the company. The company has issued annual dividends per share of 1.45, 1.3, and 1.0 USD over the last three years, respectively. These dividends have been yielding 0.89%, 0.71%, and 0.58% in 2021, 2022, and 2023, respectively.

This averages out to a dividend yield of 0.73%. This increase in dividends reflects the company’s increased financial stability and performance over the past few years. This move will likely make ZOETIS INC even more attractive to potential investors.

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Zoetis Inc. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Zoetis Inc. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Zoetis Inc. More…

Key Ratios Snapshot

Some of the financial key ratios for Zoetis Inc are shown below. More…

Analysis

GoodWhale recently conducted an analysis of ZOETIS INC‘s wellbeing. According to our Star Chart, ZOETIS INC is strong in dividend, growth, profitability, and medium in asset. It had a high health score of 9/10 with regard to its cashflows and debt, and can safely ride out any crisis without the risk of bankruptcy. We classified ZOETIS INC as a ‘rhino’ – i.e. a company that has achieved moderate revenue or earnings growth. Given these strong metrics, we believe that ZOETIS INC could be of interest to investors looking for steady, dependable returns with low risk. Such investors may be particularly interested in the company’s strong dividend, as well as its promising growth potential. More…

Peers

Zoetis Inc. is a global animal health company that develops, manufactures, and markets a wide range of veterinary products. The company’s products include vaccines, parasiticides, pharmaceuticals, diagnostics, and biologics. Zoetis Inc. has a broad portfolio of products that are used in the prevention, treatment, and control of disease in animals. The company’s competitors include BioGaia AB, Krka d.d., and Phibro Animal Health Corp.

– BioGaia AB ($OTCPK:BIOGY)

Biogaia is a Swedish biotech company that markets probiotic products for infants, children, and adults. The company’s products are based on the lactic acid bacterium Lactobacillus reuteri, which is found naturally in the human gastrointestinal tract. Biogaia’s products are sold in over 60 countries worldwide.

Biogaia’s market cap is 800.05M as of 2022. The company has a Return on Equity of 10.86%. Biogaia’s products are based on the lactic acid bacterium Lactobacillus reuteri, which is found naturally in the human gastrointestinal tract. Biogaia’s products are sold in over 60 countries worldwide.

– Krka d.d. ($LTS:0HLK)

Krka d.d. is a Slovenian pharmaceutical company. It is the largest pharmaceutical company in Slovenia and one of the largest in the Balkans. The company was founded in 1959 and is headquartered in Novo mesto. Krka d.d. has a market cap of 2.77B as of 2022 and a Return on Equity of 12.85%. The company’s main products are prescription drugs, over-the-counter drugs, and medical devices.

– Phibro Animal Health Corp ($NASDAQ:PAHC)

Phibro Animal Health Corporation is a diversified animal health and specialty ingredients company with products in over 100 countries. The company’s products are sold through veterinarians, distributors, and feed stores. Phibro Animal Health Corporation’s mission is to improve the health and productivity of animals. The company’s products are used in a variety of animals, including cattle, swine, poultry, and aquaculture. Phibro Animal Health Corporation’s products are designed to improve the health and productivity of animals while providing a safe and healthy environment for them to live in.

Summary

Zoetis Inc., a leading global animal health company, recently announced an increase in its quarterly dividend to $0.432 per share, a 15% increase from the previous quarter. This is a significant move for the company as it demonstrates confidence in its financial condition and future prospects. Investors should consider the dividend increase when determining whether Zoetis is a viable investment opportunity.

Additionally, investors should pay attention to the company’s recent performance and market outlook to gain a better understanding of where the company is likely to go in the future. Analyzing the company’s financials, competitive dynamics, product and service offerings, and management team can provide further insight into the company’s potential for growth and value creation.